Propanc Biopharma, Inc.

PPCB Nasdaq CIK: 0001517681

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 302/6 BUTLER STREET, CAMBERWELL, VICTORIA, C3, 3124
Mailing Address 302/6 BUTLER STREET, CAMBERWELL, VICTORIA, C3, 3124
Phone 61-03-9882-0780
Fiscal Year End 0630
EIN 330662986

Financial Overview

FY2025

-$1.82M
Net Income
$13.91M
Stockholders' Equity
$-14.85
EPS

Recent SEC Filings

Form Type Date Filed Document
S-1 IPO registration statement February 2, 2026 View on SEC
8-K Current report of material events January 7, 2026 View on SEC
S-1 IPO registration statement December 30, 2025 View on SEC
10-Q Quarterly financial report November 14, 2025 View on SEC
SCHEDULE 13G/A Passive ownership amendment November 14, 2025 View on SEC
8-K Current report of material events November 10, 2025 View on SEC
8-K Current report of material events October 14, 2025 View on SEC
10-K Annual financial report September 29, 2025 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) August 19, 2025 View on SEC
8-K Current report of material events August 19, 2025 View on SEC

Annual Reports

10-K September 29, 2025
  • Approved for new clinical trial in Australia.
  • Early lab results suggest PRP might block cancer spread.
View Analysis

Material Events

8-K Financial Distress January 7, 2026
High Impact
  • Propanc Biopharma, Inc. received a notice from Nasdaq for its stock price falling below the required minimum of $1.00 per share.
  • The company is at risk of being delisted from The Nasdaq Capital Market if it doesn't regain compliance.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.